What Medicares Temporary Program Covering GLP-1s for Obesity Means for Beneficiaries The Centers for Medicare & Medicaid Services (CMS) has released a memo fleshing out the design of a short-term program providing Medicare coverage of GLP-1s for obesity in 2026 ahead of a multi-year demonstration program beginning in 2027
Here is what the key trials showed
Type 2 diabetes and cardiovascular disease: have all risk factors the same strength
When to Consider Medication Adjustments If Ozempic causes big side effects or doesnt work well, your doctor might change your treatment
Mo X, Shen L, Cheng R, Wang P, Wen L, Sun Y, et al
Comprehensive programs often include: Initial consultation Medical evaluation Nutrition support Activity recommendations Progress monitoring Dose adjustments Follow-up appointments The goal is to support sustainable, long-term health improvements rather than rapid short-term weight loss